Phase I/II Trial of the A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02990416

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:36:21.273676+00:00

Published At

2016-12-13T00:00:00+00:00

Record Updated At

2016-12-13

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Stage IV Melanoma"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2016-12-13"

protocolSection.identificationModule.nctId

"NCT02990416"

protocolSection.identificationModule.officialTitle

"Phase I/II Trial of the A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma"

protocolSection.statusModule.overallStatus

"UNKNOWN"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Stage IV Melanoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.